-2.48;
P < .01). Long-term combination therapy also failed to
reduce the risk of major vascular events (RR, 0.92; 95% CI,
0.84-1.03; P Â¼ .09).137
Alternate antiplatelet agents are also being investigated for secondary prevention among patients with
symptomatic carotid disease. In a recent meta-analysis
of 36 randomized clinical trials